Personalized medicine in oncology: the future is now. (Q51828510)

13 April 2018

review article

1 reference

title

Personalized medicine in oncology: the future is now. (English)

1 reference

13 April 2018

main subject

personalized medicine

1 reference

Richard L Schilsky

1

1 reference

13 April 2018

publication date

1 May 2010

1 reference

13 April 2018

Nature Reviews Drug Discovery

published in

1 reference

13 April 2018

volume

9

1 reference

13 April 2018

issue

5

1 reference

13 April 2018

page(s)

363-366

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1038/nrd3181

exact match

0 references

cites work

Molecular subtypes in breast cancer evaluation and management: divide and conquer

1 reference

A gene-expression signature as a predictor of survival in breast cancer

31 March 2020

1 reference

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

31 March 2020

1 reference

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

31 March 2020

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

31 March 2020

1 reference

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

31 March 2020

1 reference

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

31 March 2020

1 reference

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer

31 March 2020

1 reference

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

31 March 2020

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

31 March 2020

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

31 March 2020

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer

31 March 2020

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

31 March 2020

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

31 March 2020

1 reference

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

31 March 2020

1 reference

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD3181

1 reference

13 April 2018

1 reference

13 April 2018